



Mayzent in India

The CDSCO named-patient coordination pathway — indicative 2026

NEUROLOGY · ACTIVE SECONDARY PROGRESSIVE MS

The clinical situation

Mayzent (siponimod) is an oral selective S1P1/S1P5 receptor modulator FDA-approved for active secondary progressive multiple sclerosis (SPMS), relapsing-remitting MS, and clinically isolated syndrome in adults. Manufactured by Novartis. CYP2C9 genotyping is required before initiation; the starter titration pack steps up over five days to the genotype-dependent maintenance dose (typically 2 mg daily). Pre-treatment workup covers baseline ECG, CBC with absolute lymphocyte count, LFTs, varicella serology, and ophthalmologic baseline per FDA labelling.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your neurologist documents active SPMS, MRI review, disability progression, and Mayzent rationale.
- 2 Baseline workup.** CYP2C9 genotyping, ECG, CBC with lymphocyte count, LFTs, varicella serology, ophthalmology baseline per FDA labelling.
- 3 CDSCO named-patient application.** Physician or hospital pharmacy files clinical rationale, patient reference, CYP2C9 result, titration plan, and chain-of-custody commitment.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner with controlled-ambient shipment.
- 5 Arrival & first dose.** Dispensing pharmacy releases the starter titration pack; first-dose monitoring arranged per protocol.

Indicative economics

Reference US cash-pay range: USD 100,000–120,000 per year of Mayzent (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete CDSCO application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody from Novartis authorised distribution.

Documentation. Physician kit tailored to CDSCO review, with CYP2C9 genotyping and S1P class safety annex. **Logistics.**

Controlled-ambient internationally tracked shipment. **Concierge case lead.** Named point of contact for family and physician through titration and monthly refills. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Mayzent × India first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/mayzent-india.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team